BlueDot, a disease containment technology spinout set up by St Michael’s Hospital and Mars Innovation, has secured series A capital.

BlueDot, a Canada-based disease containment technology developer spun out in partnership with multi-institution commercialisation firm Mars Innovation, has attracted C$9.2m ($6.9m) in series A funding, BetaKit reported yesterday. Insurance co-operative The Co-operators and Canadian government-owned venture arm BDC Capital co-led the round, investing through their respective funds Insurtech and Women in Technology Venture Fund. Founded…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.